BRAIN GLUTAMATE DECARBOXYLASE IN PARKINSON'S DISEASE WITH PARTICULAR REFERENCE TO A PREMORTEM SEVERITY INDEX

Brain ◽  
1985 ◽  
Vol 108 (2) ◽  
pp. 301-313 ◽  
Author(s):  
J. C. MONFORT ◽  
F. JAVOY-AGID ◽  
J. J. HAUW ◽  
B. DUBOIS ◽  
Y. AGID
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Glutamate Decarboxylase ◽  
Severity Index

The clinical impression of severity index for Parkinson's disease: International validation study

2009 ◽  
Vol 24 (2) ◽  
pp. 211-217 ◽  
Author(s):  
Pablo Martínez-Martín ◽  
Carmen Rodríguez-Blázquez ◽  
Maria João Forjaz ◽  
Jesús de Pedro ◽  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Validation Study ◽  
Severity Index ◽  
Clinical Impression

scholarly journals Insomnia and autonomic dysfunction may identify patients at risk for developing early Parkinson's disease dementia

2019 ◽  
Author(s):  
Anamaria Jurcau ◽  
Vharoon Sharma Nunkoo
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Autonomic Dysfunction ◽  
Odds Ratio ◽  
Rating Scale ◽  
Demographic Data ◽  
Severity Index ◽  
Complex Evaluation ◽  
Patients At Risk

Abstract Background: The prospective study aims at identifying features predictive of early onset of dementia in patients with Parkinson's disease (PD). Methods: 89 non-demented PD patients underwent a complex evaluation (demographic data, UPDRS, Unified Multiple System Atrophy Rating Scale - UMSAR, Insomnia Severity Index - ISI, Neuro-Psychiatric Inventory - NPI, Hamilton Depression Rating Scale - HDRS, Mini Mental State Examination) at baseline and at 3-year follow-up. Results: At 3-year follow-up 43.8% of patients developed dementia. An ordinal regression of MMSE at follow-up showed that dementia developed in patients with autonomic dysfunctions (odds ratio 16.18, 95% CI 3.16 to 82.77, p = 0.001), old age (odds ratio 1.24, 95% CI 1.11 to 1.39, p < 0.001), and insomnia (odds ratio 1.23, 95% CI 1.09 to 1.38, p = 0.001). Conclusion: Patients with signs of autonomic dysfunction and insomnia are at higher risk for developing dementia and deserve closer monitoring of cognitive symptoms.

Glutamate decarboxylase-67 messenger RNA expression in normal human basal ganglia and in Parkinson's disease

Neuroscience ◽  
1996 ◽  
Vol 75 (2) ◽  
pp. 389-406 ◽  
Author(s):  
A.P Nisbet ◽  
D.J Eve ◽  
A.E Kingsbury ◽  
S.E Daniel ◽  
C.D Marsden ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Basal Ganglia ◽  
Glutamate Decarboxylase ◽  
Messenger Rna ◽  
Rna Expression ◽  
Normal Human

Evaluation of Efferent Auditory System and Hearing Quality in Parkinson's Disease: Is the Difficulty in Speech Understanding in Complex Listening Conditions Related to Neural Degeneration or Aging?

2020 ◽  
pp. 1-9
Author(s):  
Nuriye Yıldırım Gökay ◽  
Bülent Gündüz ◽  
Fatih Söke ◽  
Recep Karamert
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Auditory System ◽  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Pure Tone Audiometry ◽  
Auditory Pathway ◽  
Normal Hearing ◽  
System Function ◽  
Distortion Product

Purpose The effects of neurological diseases on the auditory system have been a notable issue for investigators because the auditory pathway is closely associated with neural systems. The purposes of this study are to evaluate the efferent auditory system function and hearing quality in Parkinson's disease (PD) and to compare the findings with age-matched individuals without PD to present a perspective on aging. Method The study included 35 individuals with PD (mean age of 48.50 ± 8.00 years) and 35 normal-hearing peers (mean age of 49 ± 10 years). The following tests were administered for all participants: the first section of the Speech, Spatial and Qualities of Hearing Scale; pure-tone audiometry, speech audiometry, tympanometry, and acoustic reflexes; and distortion product otoacoustic emissions (DPOAEs) and contralateral suppression of DPOAEs. SPSS Version 25 was used for statistical analyses, and values of p < .05 were considered statistically significant. Results There were no statistically significant differences in the pure-tone audiometry thresholds and DPOAE responses between the individuals with PD and their normal-hearing peers ( p = .732). However, statistically significant differences were found between the groups in suppression levels of DPOAEs and hearing quality ( p < .05). In addition, a statistically significant and positive correlation was found between the amount of suppression at some frequencies and the Speech, Spatial and Qualities of Hearing Scale scores. Conclusions This study indicates that medial olivocochlear efferent system function and the hearing quality of individuals with PD were affected adversely due to the results of PD pathophysiology on the hearing system. For optimal intervention and follow-up, tasks related to hearing quality in daily life can also be added to therapies for PD.

Accessible Internet Training for People With Aphasia and Parkinson's Disease

2004 ◽  
Vol 9 (2) ◽  
pp. 10-13
Author(s):  
Linda Worrall ◽  
Jennifer Egan ◽  
Dorothea Oxenham ◽  
Felicity Stewart
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease

Voice Treatment for Individuals With Parkinson's Disease

2007 ◽  
Vol 12 (1) ◽  
pp. 2-11
Author(s):  
Lorraine Ramig ◽  
Cynthia Fox
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Voice Treatment
Sign in / Sign up

Export Citation Format

Share Document